| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H4N4O2 |
| Molecular Weight | 152.1109 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1NC2=C(C=NN2)C(=O)N1
InChI
InChIKey=HXNFUBHNUDHIGC-UHFFFAOYSA-N
InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)
| Molecular Formula | C5H4N4O2 |
| Molecular Weight | 152.1109 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Oxypurinol is an active metabolite of allopurinol and is an inhibitor of xanthine oxidase. Cardiome Pharma developed oxipurinol for the treatment of allopurinol-intolerant hyperuricemia (gout) and for the treatment of congestive heart failure. It is known, that inhibition of xanthine oxidase can improve myocardial work efficiency by sensitizing cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function. However, all these studied were discontinued.
